Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
How have the results of the SUNMO trial (mosunetuzumab + polatuzumab) impacted your treatment choices for Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma?
Related Questions
Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How do you approach patient with CLL/SLL limited to the prostate?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
How would you manage a healthy young adult patient with nodular lymphocyte predominant Hodgkin lymphoma with steroid-responsive severe hemolytic anemia and no other symptoms?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
How would you approach treatment with BV-CHP regimen in a patient with newly diagnosed CD30+ ALK- anaplastic large cell lymphoma at high risk for cardiotoxicity?
How do you approach the outpatient management of bispecific antibody therapy for hematologic malignancies?
